

Level 9, 40 Mercer Street, Wellington 6011 PO Box 10-254, Wellington 6143, New Zealand

> Phone 64-4-460-4990 Fax 64-4-460-4995 Information line 0800 66 00 50

> > enquiry@pharmac.govt.nz www.pharmac.govt.nz

3 August 2017

Via email: fyi-request-6143-c03d041f@requests.fyi.org.nz

Dear Virginia

REQUEST FOR INFORMATION

Thank you for your request dated 06 July 2017 under the Official Information Act 1982 (OIA), for information relating to the annual cost of providing the HPV vaccine (Gardasil/Gardasil 9).

You also requested the annual cost to be broken down into the cost per child.

We have interpreted your request to mean the cost (based upon the manufacturer's price) of Gardasil payable to the pharmaceutical supplier and the cost broken down into the cost per injection.

The total annual cost for Gardasil by financial year (1 July – 30 June):

- 2014/15 was \$10,048,700;
- 2015/16 was \$10,106,525; and
- 2016/17 was \$15,775,095.

The cost per injection is as follows:

Gardasil 9 (2015): \$141.50Gardasil 4 (2016): \$128.50

Please note the actual price PHARMAC pays to the pharmaceutical supplier for Gardasil is confidential and differs to the manufacturer's price payable as set out above and as such this information is being withheld under the OIA, as we consider this necessary to:

- protect information where the making available of the information would be likely to unreasonably prejudice the commercial position of the person who supplied or who is the subject of the information (section 9(2)(b)(ii));
- protect information which is subject to an obligation of confidence or which any person
 has been or could be compelled to provide under the authority of any enactment, where
 the making available of the information would be likely to prejudice the supply of similar
 information, or information from the same source, and it is in the public interest that such
 information should continue to be supplied (section 9(2)(ba)(i)); and
- enable PHARMAC to carry out, without prejudice or disadvantage, commercial activities (section 9(2)(i)).

As required under the OIA, we also considered whether, in the circumstances, the withholding of this information was outweighed by other considerations which render it

desirable, in the public interest, to make this information available. In this case we did not consider that the public interest outweighed the reasons for withholding the information.

Please note you have the right, by way of complaint under section 28(3) of the OIA to an Ombudsman, to seek an investigation and review of our decision.

We trust that the provision of this information answers your query, if you have any further questions please feel free to contact us again.

Yours sincerely

Jude Culiny

Jude Urlich

Director, Engagement and Implementation

A1051859 qA43816 2